Compare Davita Inc (DVA) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs 22nd Century Group Inc — how do they compare? Davita Inc trades at $179.25 (market cap $11.29B), while 22nd Century Group Inc trades at $0.81 (market cap $621.67K). The key difference: Davita Inc is far larger — about 18160.8× 22nd Century Group Inc's market cap, and Davita Inc is trading nearer its 52-week high, 22nd Century Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and 22nd Century Group Inc for 32 Days on average.
| DVA | XXII | |
|---|---|---|
Market Cap | $11.29B | $621.67K |
Volume | 582,204 | 45,625 |
Sector | Health | Consumer Staples |
52-Week High | $240.96 | $483.00 |
52-Week Low | $103.87 | $0.80 |
Typical Hold Time | 114 Days | 32 Days |
Enterprise Value | $24.01B | -$3.69M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $177.02, up 0.14% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a P/E of 15 and revenue growth from $13.64B in 2025 to projected $14.0B in 2026. Recent news highlights value-based care expansion with Humana and institutional buying by BlackRock. Technical indicators show resistance at $179 and support at $175, with RSI neutral at 59.72.
DVA presents a mixed outlook: analyst consensus targets $235.67 (33% upside) with 43% buy ratings, but technicals suggest near-term pressure. Key opportunities include consistent EPS beats and partnership growth, while risks involve rising debt-to-asset ratio (65.55% in 2025) and regulatory exposure. Net cash flow turned negative in 2025, requiring monitoring.
XXII trades at $0.8116, down 8.96% in the last session, with a bearish technical signal from moving averages. The company shows negative profitability metrics including -76.01% net income margin and -284.5% ROE, though valuation ratios appear low with P/S of 0.08 and P/B of 0.03. Recent news highlights regulatory progress in reduced-nicotine tobacco initiatives in France and Europe.
While analyst consensus is 75% buy with a $1,240 price target suggesting significant upside, fundamental challenges persist with consecutive earnings misses and negative cash flow from operations. The stock faces execution risk in commercializing its reduced-nicotine platform amid ongoing losses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
